Determination of a novel anticancer c-Met inhibitor LS-177 in rat plasma and tissues with a validated UPLC-MS/MS method: application to pharmacokinetics and tissue distribution study.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Biomedical chromotography

• Publication date

  2015-07-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1002/bmc.3397PMID 25472760
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Inhibitors of the TAM subfamily of tyrosine kinases: synthesis and biological evaluation.

  2013cited by this paper
• Abstract C272: Antitumor activity of the dual AXL/c-Met inhibitor CEP-40783 in Champions primary TumorGraft™ models of human non-small cell lung cancer (NSCLC).

  2013cited by this paper
• Discovery of novel 4-(2-fluorophenoxy)quinoline derivatives bearing 4-oxo-1,4-dihydrocinnoline-3-carboxamide moiety as c-Met kinase inhibitors.

  2013cited by this paper
• Design, synthesis, and structure-activity relationships of novel 6,7-disubstituted-4-phenoxyquinoline derivatives as potential antitumor agents.

  2013cited by this paper
• A Comparison of the pharmacokinetics of the anticancer MET inhibitor foretinib free base tablet formulation to bisphosphate salt capsule formulation in patients with solid tumors

  2012cited by this paper
• A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumors

  2012cited by this paper
• Foretinib (GSK1363089), an Orally Available Multikinase Inhibitor of c-Met and VEGFR-2, Blocks Proliferation, Induces Anoikis, and Impairs Ovarian Cancer Metastasis

  2011cited by this paper
• An adjacent arginine, and the phosphorylated tyrosine in the c‐Met receptor target sequence, dictates the orientation of c‐Cbl binding

  2011cited by this paper
• Small molecule c-Met kinase inhibitors: a review of recent patents

  2010cited by this paper
• Discovery of small molecule c-Met inhibitors: Evolution and profiles of clinical candidates.

  2010cited by this paper
• Down-regulation of c-Met expression inhibits human HCC cells growth and invasion by RNA interference.

  2010cited by this paper
• Potent preclinical antitumor activity of MGCD265, an oral Met/VEGFR kinase inhibitor in phase II clinical development, in combination with taxanes or erlotinib.

  2010cited by this paper
• MET receptor tyrosine kinase as a therapeutic anticancer target.

  2009cited by this paper
• Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.

  2009cited by this paper
• The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma.

  2009cited by this paper
• N-(4-(6,7-Disubstituted-quinolin-4-yloxy)-3-fluorophenyl)-2-oxo-3-phenylimidazolidine-1-carboxamides: a novel series of dual c-Met/VEGFR2 receptor tyrosine kinase inhibitors.

  2009cited by this paper
• Discovery of orally active pyrrolopyridine- and aminopyridine-based Met kinase inhibitors.

  2008cited by this paper
• 405 POSTER A phase I dose-escalation study of the safety and pharmacokinetics of a XL184, a VEGFR and Met kinase inhibitor, administered orally to subjects with advanced malignancies

  2006cited by this paper
• c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention.

  2005cited by this paper
• Nanoparticulate systems for brain delivery of drugs.

  2001cited by this paper

• Microwave assisted extraction for the determination of antineoplastic compounds in marine fish

  2019cites this paper
• Ultra-high performance liquid chromatography-MS/MS (UHPLC-MS/MS) in practice: analysis of drugs and pharmaceutical formulations

  2019cites this paper
• CD-PLLD co-delivering docetaxel and MMP-9 siRNA plasmid for nasopharyngeal carcinoma therapy in vivo.

  2017cites this paper
• Folate-targeted star-shaped cationic copolymer co-delivering docetaxel and MMP-9 siRNA for nasopharyngeal carcinoma therapy

  2016cites this paper
• miR‐144‐3p exerts anti‐tumor effects in glioblastoma by targeting c‐Met

  2015cites this paper